Author's response to reviews

Title: Fatal interstitial lung disease associated with oral erlotinib therapy

Authors:

Demosthenes Makris (appollon7@hotmail.com)
Arnaud Scherpereel (a-scherpereel@chru-lille.fr)
Marie Christine Copin (m-copin@chru-lille.fr)
Guillaume Colin (belgutou@yahoo.fr)
Luc Brun (lbrun@chru-lille.fr)
Jean-Jacques Lafitte (jjlafitte@chru-lille.fr)
Charles Hugo Marquette (C-MARQUETTE@CHRU-LILLE.FR)

Version: 3 Date: 24 June 2007

Author's response to reviews:

To:

The Editor, BMC Cancer

June, 23th, 2007

Dear Editor,

Please find enclosed our revised manuscript titled “Fatal interstitial lung disease associated with oral erlotinib therapy” by Demosthenes Makris et al. This manuscript reports a case of erlotinib (Tarceva) associated Interstitial Lung Disease (ILD) in a patient with disseminated non-small cell lung cancer (NSCLC). In this revised version of the manuscript we modified and corrected the text according to your requirements by adding acknowledgements, statement of interest and authors contribution sections.

We hope that this revised version will be considered as suitable for publication in BMC Cancer.

I will be the corresponding author and deal with all prepublications issues.

Thank you in advance for your kind cooperation.

Sincerely Yours,

Arnaud Scherpereel, M.D., Ph.D.
Assistant Professor

Service de Pneumologie et d'Oncologie Thoracique

Hopital Calmette - CHRU de Lille

59037 LILLE Cedex (France)

Tel: (33) (0)3 20 44 49 98

Fax: (33) (0)3 20 44 56 11

a-scherpereel@chru-lille.fr